

References

1. Ansell D, Feehally J, Feest TG *et al.* *New adult patients starting renal replacement therapy in the UK in 2006. UK Renal Registry: the tenth annual report 2007.* Bristol, UK: UK Renal Registry, <http://www.renalreg.com/Report-Area/Report%202008/Chapter03.pdf>
2. Lewis MA, Shaw J, Reid C *et al.* *Chapter 13: demography and management of childhood established renal failure in the UK.* <http://www.renalreg.com/reports/renal-registry-reports/2006/>
3. Lewis M, Shaw J, Reid C *et al.* Demography and management of childhood established renal failure in the UK (chapter 13). *Nephrol Dial Transplant* 2007; 22, Suppl 7: 165–175
4. Lewis MA. Demography of renal disease in childhood. *Semin Fetal Neonatal Med* 2008; 13: 118–124
5. Schaerer K, Chantler C, Brunner FP *et al.* Combined report on regular dialysis and transplantation of children in Europe, 1976. *Proc Eur Dial Transplant Assoc* 1975;59–105
6. Neild GH. What do we know about chronic renal failure in young adults? I. Primary renal disease. *Pediatr Nephrol* 2009; 24: 1913–1919
7. UK Government. *Table 1. Mid-2007 population estimates: estimated resident population by broad age-group and sex. Key Population and Vital Statistics 2007.* Office for National Statistics, 2009; http://www.statistics.gov.uk/downloads/theme_population/KPVS34-2007/KPVS2007.pdf
8. Fivush BA, Jabs K, Neu AM *et al.* Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS. North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 1998; 12: 328–337
9. NAPRTCS. *North American Pediatric Renal Trials and Collaborative Studies.* <http://spitfire.emmes.com/study/ped/annlrept/annlrept2006.pdf>. 2006
10. ANZDATA. *The 30th Annual Report (2007).* <http://www.anzdata.org.au/ANZDATA/AnzdataReport/download.htm#30th%20Report>. 2008
11. Ardissino G, Dacco V, Testa S *et al.* Epidemiology of chronic renal failure in children: data from the ItalKid project. *Pediatrics* 2003; 111: e382–e387
12. Wingen AM, Fabian-Bach C, Schaefer F *et al.* Randomised multi-centre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. *Lancet* 1997; 349: 1117–1123
13. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). *J Am Soc Nephrol* 2003; 14: 2618–2622
14. Neild GH, Thomson G, Nitsch D *et al.* Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys. *BMC Nephrol* 2004; 5: 12
15. Simon P, Ramee MP, Autuly V *et al.* Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. *Kidney Int* 1994; 46: 1192–1198
16. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. *Nephrol Dial Transplant* 1997; 12: 418–426
17. Wyatt RJ, Julian BA, Baehler RW *et al.* Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. *J Am Soc Nephrol* 1998; 9: 853–858
18. Briganti EM, Dowling J, Finlay M *et al.* The incidence of biopsy-proven glomerulonephritis in Australia. *Nephrol Dial Transplant* 2001; 16: 1364–1367
19. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Frequency of renal pathology in Spain 1994–1999. *Nephrol Dial Transplant* 2002; 17: 1594–1602
20. Simon P, Ramee MP, Boulahrouz R *et al.* Epidemiologic data of primary glomerular diseases in western France. *Kidney Int* 2004; 66: 905–908
21. Rychlik I, Jancova E, Tesar V *et al.* The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994–2000. *Nephrol Dial Transplant* 2004; 19: 3040–3049
22. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. *Kidney Int* 2004; 66: 920–923
23. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? *Kidney Int* 2006; 69: 1455–1458
24. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Clinicopathologic correlations of renal pathology in Spain. *Kidney Int* 2004; 66: 898–904
25. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. *Q J Med* 1987; 64: 709–727
26. Goto M, Wakai K, Kawamura T *et al.* A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. *Nephrol Dial Transplant* 2009; 24: 3068–3074
27. *Finnish Registry for Kidney Diseases. Report 2006.* http://www.musli.fi/fin/munuaistautirekisteri/finnish_registry_for_kidney_diseases/

Received for publication: 20.5.09; Accepted in revised form: 9.11.09

Nephrol Dial Transplant (2010) 25: 1032–1033

doi: 10.1093/ndt/gfp648

Advance Access publication 3 December 2009

Cystinosis and Mickey Mouse

Alan Medlar and Robert Kleta

Centre for Nephrology, University College London, London, UK

Correspondence and offprint requests to: Robert Kleta; E-mail: r.kleta@ucl.ac.uk

What could the knockout mouse and Mickey Mouse possibly have in common? They appear as polar opposites. One inhabits a laboratory, scorned for the latest failed experiment. The other, more at home in the glitz of Hollywood, is adored by all [1]. Aside from the ears though, the

similarities are profound, whereas Mickey serves as the comic-everyman, the knockout mouse enjoys the dubious honour of being every man's (or woman's) genetic stand-in.

Cystinosis, like Mickey Mouse, is known to all paediatric nephrologists, less so to those specializing in adults.

It was first diagnosed over a century ago in children exhibiting a failure to thrive, leading to premature death. It was subsequently recognized as a cystine-related lysosomal storage disorder [2]. Untreated patients present in infancy first with renal Fanconi syndrome and then, at about 10 years of age, suffer glomerular kidney failure necessitating renal replacement therapy [3]. Following the cloning of the gene, CTNS, 10 years ago, molecular studies have proved patients affected with this problem are present all over the world. Years before, smart biochemists had discovered a specific treatment—cysteamine [4]. Clinical trials and treatment over the past 40 years have proved without doubt that this treatment helps. In fact, it helps a lot [5]. Contrast this with as recently as the 1960s, when patients would still have died during childhood. Nowadays, they can expect to live into their fifties at the very least [6], illustrating the importance of medical doctors and nephrologists of all stripes being able to diagnose and treat this condition.

Advances in biomedical science have made genetically modified mice readily available. Since their conception by Oliver Smithies and colleagues, the study of knockout mice has almost become a science in its own right [7].

Studying knockout mice, like human patients, takes time, dedication and expert knowledge. Cloning a gene and creating a knockout mouse as proof of principle still counts as a major accomplishment in medical research today. Dr. Antignac's group not only cloned the gene [8], but also created the first knockout mouse for cystinosis [9]. Unfortunately, this particular mouse did not show what was expected. Despite biochemical measurements pointing towards cystine-related lysosomal storage, no signs or symptoms of kidney failure of either tubular or glomerular origin could be appreciated. Quite a shame; imagine Mickey Mouse, but without the laughter!

Undeterred, Dr. Antignac and her team revisited the issue, creating another knockout mouse and, like all good mice thrown into the spotlight, this one did not disappoint. Their new mouse shows kidney involvement [10].

What went wrong the first time? We believe it was no fault of the method. We must appreciate the depth of some mice to be greater than the comic spills of cartoon characters. It turns out that knockout mice are not as simple as we once thought. Life is complicated enough and knocking out a gene does not always create reproducible and unique phenotypes. Much like patients within the same family with variations of the same monogenetic disease, the mice can be quite different from each other. Knockout mice

have been bred for a purpose, using inbred mouse strains, from all over the world for many years. This can translate into actually having many biased gene functions. In this case, the first knockout mouse created for cystinosis on the genetic background of 129Sv and C57BL/6 probably had some genes functioning in a protective manner in comparison to the new knockout mouse created on the background of C57BL/6 mice. Additionally, having FVB/N mice as background for this knockout produced no kidney findings whatsoever. It would be quite nice to compare genomes of the three mouse strains to better understand their differences and potentially help explain protection against kidney disease.

Dr. Antignac's group has created another mouse to play foil to man, who will certainly help improve our understanding, specifically, of cystinosis and, broadly, of kidney disease. We welcome this new mouse in our community.

Conflict of interest statement. None declared.

References

- Farrell MM, Pollack MA. Mickey Mouse neurology. Neurological disorders in children visiting central Florida. *J Fla Med Assoc* 1990; 77: 600–601
- Kleta R, Gahl WA. Cystinosis: antibodies and healthy bodies. *J Am Soc Nephrol* 2002; 13: 2189–2191
- Gahl WA, Thoene JG, Schneider JA. Cystinosis. *N Engl J Med* 2002; 347: 111–121
- Thoene JG, Oshima RG, Crawhall JC *et al.* Cystinosis. Intracellular cystine depletion by aminothiols *in vitro* and *in vivo*. *J Clin Invest* 1976; 58: 180–189
- Kleta R, Bernardini I, Ueda M *et al.* Long-term follow-up of well-treated nephropathic cystinosis patients. *J Pediatr* 2004; 145: 555–560
- Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. *Ann Intern Med* 2007; 147: 242–250
- Manis JP. Knock out, knock in, knock down—genetically manipulated mice and the Nobel Prize. *N Engl J Med* 2007; 357: 2426–2429
- Town M, Jean G, Cherqui S *et al.* A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. *Nat Genet* 1998; 18: 319–324
- Cherqui S, Sevin C, Hamard G *et al.* Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. *Mol Cell Biol* 2002; 22: 7622–7632
- Nevo N, Chol M, Bailleux A *et al.* Renal phenotype of the cystinosis mouse model is dependent upon genetic background. *Nephrol Dial Transplant* 2009; doi 10.1093/ndt/gfp553 [epub ahead of print]

Received for publication: 27.10.09; Accepted in revised form: 5.11.09